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Relationship Between Non-small Cell Lung Cancer
FDG Uptake at PET, Tumor Histology, and Ki-67
Proliferation Index
Hubert Vesselle, PhD, MD,* Alexander Salskov, BA,* Eric Turcotte, MD,* Linda Wiens, BS,*
Rodney Schmidt, MD, PhD,† C. Diana Jordan, MD,† Eric Vallie`res, MD,‡
and Douglas E. Wood, MD‡
Introduction: We compared primary non-small cell lung cancer
(NSCLC) 18F-fluorodeoxyglucose (FDG) uptake at positron emis-
sion tomography (PET) to tumor histologic features and Ki-67
proliferation index. This large, prospectively-recruited patient co-
hort has previously been analyzed based on differences in FDG
uptake across stage groups; the current analysis adds further dimen-
sions to this characterization.
Materials and Methods: One hundred seventy-eight patients with
potentially-resectable NSCLC were scanned with FDG PET before
therapy. A partial volume correction algorithm was used to correct
FDG uptake values for their dependence on tumor size. Primary
tumor resection specimens, core biopsies, and biopsies of metastatic
lymph nodes were used to assess each tumor’s NSCLC histologic
subtype, degree of differentiation, and Ki-67 proliferation index.
Results: Bronchioalveolar carcinomas were found to have lower
FDG uptake at PET and lower Ki-67 scores than any other histologic
subtype. Non-bronchioalveolar adenocarcinomas had lower FDG
uptake and Ki-67 scores than squamous cell carcinomas or large cell
undifferentiated carcinomas. Better differentiated NSCLCs had
lower FDG uptake and Ki-67 scores than more poorly differentiated
NSCLCs. There was a significant positive correlation between FDG
uptake and Ki-67 scores. Partial volume correction increased the
strength of this correlation, while also diminishing the strong posi-
tive correlation between FDG uptake and tumor size.
Conclusions: There are significant differences in NSCLC FDG
uptake across histologic subtypes and differentiation groups. These
differences parallel nearly identical differences in Ki-67 scores,
implying that differences in NSCLC tumor cell proliferation may
give rise to commensurate differences in tumor glucose metabolism.
Key Words: Positron emission tomography; Non-small cell lung
cancer; histology; Ki-67.
(J Thorac Oncol. 2008;3: 971–978)
Primary lung cancer remains the leading cause of cancerdeath in the United States with an estimated 174,470 new
diagnoses and 162,460 deaths in 2006.1 Non-small cell lung
cancer (NSCLC) accounts for approximately 80% of new
diagnoses and includes the histologic subtypes adenocarci-
noma, squamous cell carcinoma, large cell undifferentiated
carcinoma, and mixed histologies. Bronchioalveolar carci-
noma (BAC) is a noninvasive and often slow-growing sub-
type of adenocarcinoma, characterized by spread along the
alveolar septae.
The most significant predictor of prognosis in NSCLC
is the cancer’s stage at presentation,2 which also guides
treatment decisions. Nevertheless, each stage remains a het-
erogeneous group comprised of tumors with different re-
sponses to treatment and overall outcomes. This observation
is highlighted by the fact that even in stage IA NSCLC, the
5-year survival after a complete resection is only 67%,2
meaning that 33% of tumors in this stage group ultimately
recur, leading to death. Recent studies in stage IB and II
NSCLC have shown that after resection, adjuvant chemother-
apy can improve outcome,3,4 a welcome benefit, given the
fact that with surgery alone, only approximately 50% of
patients survive at least 5 years.2 These findings demonstrate
the need for further ways to stratify patients based on prog-
nosis within each stage group, especially as a means of
targeting adjuvant therapies to patients who would truly
benefit from them.
Positron emission tomography (PET) using the radio-
tracer 18F-fluorodeoxyglucose (FDG) enables the imaging of
glucose metabolism in vivo, which is elevated in most of
NSCLCs, providing a highly accurate, noninvasive method
for staging NSCLC.5–9 In addition, several authors have
suggested that a high FDG standardized uptake value (SUV)
within a primary tumor at PET may predict shorter survival
after treatment.10–18 However, these findings remain contro-
versial due to the wide variety of SUV cutoff values reported
to be prognostic and the fact that none of the studies ade-
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quately controlled for the effect of tumor size on both patient
prognosis and observed FDG uptake (due to partial volume
effects resulting from the limited reconstructed resolution of
the PET scanner).19
Partial volume correction (PVC) is an algorithm that
corrects for the underestimation of SUV that occurs for small
lesions due to the finite reconstructed resolution of the PET
scanner. Without PVC, partial volume effects cause an arti-
ficial correlation between tumor size and SUV. Using our GE
Advance PET scanner and imaging protocol, we have found
that PVC is necessary to accurately measure FDG uptake for
tumors smaller than 2.8 cm in average diameter.20,21 In a
previous analysis of our patient cohort,22 we showed that
while the maximum-pixel FDG standardized uptake value
(maxSUV) correlated with the size of the lesion being studied
and therefore with tumor T stage, the partial volume cor-
rected uptake value (PVCmaxSUV) was independent of tu-
mor T, N, and M stage descriptors. Furthermore, we recently
applied PVC to a large prospective cohort of NSCLC patients
scanned with FDG PET and in a multivariable analysis
including tumor stage, size, histology, and patient age, we did
not find independent prognostic significance for the tumor
maxSUV, with or without PVC.19
Having evaluated the patterns in NSCLC FDG uptake
with respect to cancer stage and prognosis, we sought to
complete our characterization of FDG uptake in NSCLC with
an analysis with respect to tumor histologic features. In the
present study, we examined our patient cohort for potential
relationships between maxSUV, PVCmaxSUV, and two bi-
ologic factors of interest in NSCLC: tumor histologic features
(histologic subtype and tumor differentiation) and prolifera-
tion index (fraction of proliferating cells) as measured by
Ki-67 score. Since we have previously analyzed this cohort
based on differences in maxSUV and PVCmaxSUV across
stage groups,22 the current study adds further dimensions to
the characterization of this series.
MATERIALS AND METHODS
Patient Selection
This study was approved by the University of Wash-
ington Human Subjects Division. Patients were recruited and
managed according to the methods described previously.22
All participants were referred to the thoracic surgery clinics at
the University of Washington Medical Center or the Veterans
Affairs Puget Sound Health Care System between February
1998 and June 2003 with a clinical diagnosis of potentially
resectable NSCLC. Patients were excluded for the following
reasons: primary lesion smaller than 1 cm (to ensure feasi-
bility of PVC), histology could not be confirmed or was
confirmed as other than NSCLC, type I diabetes, prior history
of lung cancer or other prior cancer within the previous 5
years, previous therapy or surgical staging for NSCLC
before PET, or inability to tolerate standard surgical re-
section of the tumor.
PET Imaging
All PET imaging was performed on a dedicated whole-
body PET tomograph (PET Advance©, General Electric Med-
ical Systems, Milwaukee, WI). The tracer was administered and
attenuation-corrected images were collected and analyzed ac-
cording to the methods previously described in full.22 Between
259 to 407 MBq (7 to 11 mCi) of 18F-FDG were administered
to patients intravenously after a 12 h fasting period. Emission
images of the primary tumor were acquired for 15 min, begin-
ning 45 min after injection. MaxSUV values were based on the
hottest pixel within a region of interest (ROI) drawn around the
primary tumor on an attenuation-corrected summed image span-
ning 45 to 60 min after injection. PVCmaxSUV was calculated
based on the formula20,21:
PVCmaxSUV  background SUV
 (measured max SUV  background SUV)/RC
In this formula, RC represents the recovery coefficient for a
lesion of a particular size. With our PET scanner and recon-
struction parameters, background FDG uptake contributes to
observed tumor maxSUV for tumors 2.8 cm in average
diameter because RC1 for this range of sizes, as previously
described.20,21 The average SUV in normal lung adjacent to
the tumor was used as the background.
CT Determination of Tumor Size
Tumor size was determined by averaging all 3 diame-
ters of the primary tumor, measured on the mediastinal
windows of the chest CT, using printed films. CT scans were
obtained either at our institution or by the referring physician.
Pathology
For all patients, primary tumor resection specimens,
core biopsies, and/or lymph node biopsies were reviewed by
a single expert pathologist to assess the tumor’s non-small
cell type, histologic subtype, degree of differentiation, and
Ki-67 score.
Histologic Type
Tumors displaying acinar formation, mucin production,
or intracytoplasmic mucin droplets were classified as adeno-
carcinoma. Those showing keratinization were classified as
squamous cell (epidermoid) carcinoma. Those showing no
specific differentiation by light microscopy but not classifi-
able as small cell carcinoma or carcinoid tumors were clas-
sified as large cell undifferentiated carcinoma. Non-small cell
carcinomas that were found to have neuroendocrine differen-
tiation during prestudy analyses were classified as large cell
neuroendocrine carcinomas and combined with large cell
carcinomas in statistical analyses. Adenocarcinomas that
showed exclusively surface “lepidic” spread over alveolar
septa were classified as BAC; tumors with extensive lepidic
spread but with an invasive component were classified as
adenocarcinoma. Therefore, when referring to adenocarci-
noma as a group, we excluded the BACs, which were treated
as their own group for analysis.
Histologic Differentiation
Tumor differentiation was classified as well, moderate
or poor primarily on the basis of the extent of glandular or
squamous differentiation; nuclear grade was a secondary
consideration and only affected the differentiation score if
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marked nuclear atypism and pleomorphism were present. By
definition, large cell undifferentiated carcinomas had poor
differentiation.
Ki-67 Scoring
Ki-67 is a 345 and 395 kDa nuclear protein common to
proliferating human cells, which can be detected immunohis-
tochemcially using the monoclonal antibody MIB-1.23 For
each patient from whom an adequate tumor tissue sample
was available, MIB-1 (Immunotech, Westbrook, ME;
1:1000) was used to stain a representative formalin-fixed,
paraffin-embedded section of tissue, following microwave
antigen retrieval in citrate buffer. A Vectra Elite kit with
FeCl3 intensification and hematoxylin counterstain was used
to detect MIB-1 antibody binding. The same expert patholo-
gist (RS), who was blinded to the FDG PET results, reviewed
the immunohistochemistry slides from all patients. The frac-
tion of labeled tumor cells (Ki-67 score) was visually as-
sessed over a X4 microscopic field (3 mm diameter) in the
field that contained the highest average fraction of labeled
cells.21
Statistical Methods
Nonparametric, rank-based statistical methods were chosen
because none of our measurements (maxSUV, PVCmaxSUV,
Ki-67 score, tumor size, degree of differentiation) could be
assumed to have a normal distribution. Comparisons were
therefore performed using a Kruskal–Wallis (KW) nonpara-
metric test. When significant differences were found across
multiple groups, Dunn’s nonparametric post-test was subse-
quently applied to evaluate the significance of differences
between individual pairs of groups (i.e., maxSUV of adeno-
carcinomas versus squamous cell carcinomas). Correlations
between pairs of variables (i.e., maxSUV versus Ki-67 score)
were evaluated using the Spearman rank (SR) correlation test.
The ratio of adenocarcinomas to squamous cell carcinomas
in women versus men was compared using a 2 test.
Statistical significance was assessed at the P  0.05 level.
All analyses were conducted using GraphPad Prism, ver-
sion 4.03 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Histology
Between February 1998 and June 2003, 178 subjects
(115 male, 63 female) were recruited and histologically
confirmed to have NSCLC (Table 1). As previously reported,
the distribution of stages was: 29 IA, 35 IB, 6 IIA, 19 IIB, 25
IIIA, 27 IIIB, 33 IV, and 4 with incomplete staging.22 Within
this population there were 8 BACs, 65 adenocarcinomas, 50
squamous cell carcinomas, 43 large cell undifferentiated
carcinomas, 5 carcinomas with features of mixed histologies
(4 adenosquamous and 1 squamous/large cell), and 7 carci-
nomas in which the histologic subtype could not be con-
firmed. In 6 patients with a pathologically confirmed synchro-
nous second primary lung tumor, the second tumor was not
included for analysis.
Of the 178 primary tumors studied, 11 were classified
as well differentiated, 47 as moderate, 4 as moderate to poor,
97 as poor, 5 as undifferentiated, and in 14 the differentiation
could not be confirmed. In statistical analyses related to
differentiation, those carcinomas classified as moderate to
poor were included in the moderate differentiation group and
those classified as undifferentiated were included in the poor
differentiation group.
There were no significant differences in primary tumor
size based on histologic subgroup or degree of differentiation
(Table 1). There were no significant differences in histology
or differentiation by age or sex, except that the ratio of
TABLE 1. Patients’ FDG Uptake and Ki-67 Scores by Gender and Histology
n maxSUV PVCmax SUV Ki-67 (%) Size (cm)
Sex
Female 63 10.2  4.8 11.5  4.7 47.3  25.6 3.2  1.4
Male 115 10.8  6.1 12.1  6.4 51.5  26.5 3.5  1.7
Histology
BAC 8 3.2  1.7 3.5  1.7 4.2  1.75 3.1  1.2
Adenocarcinoma* 65 9.2  5.8 10.8  6.5 40.7  23.8 2.9  1.5
Squamous 50 11.7  4.5 12.9  4.7 56.5  20.7 3.5  1.5
Large Cell 43 12.6  5.5 13.8  5.1 64.2  21.8 3.7  1.7
Mixed 5 11.0  9.9 13.2  8.5 57.0  27.2 4.1  2.9
NSCLC - NOS† 7 12.2  2.8 12.3  2.6 ‡ 4.5  1.4
Differentiation
Well 11 3.7  2.1 4.2  2.4 4.7  1.8 2.8  1.1
Moderate 51 9.0  4.4 10.2  4.0 43.4  23.4 3.0  1.5
Poor 102 11.5  5.3 13.1  5.7 58.8  22.2 3.4  1.7
Unknown 14 13.5  6.2 13.5  6.2 ‡ 4.8  1.2
Total 178 10.6  5.7 11.9  5.8 50.1  26.1 3.4  1.6
Mean  SD; *Adenocarcinoma category refers only to non-BAC adenocarcinomas; †NSCLC not otherwise specified;
‡No Ki-67 scores available. Analyses for patients in this cohort with respect to cancer stage and T, N, and M descriptors
have previously been reported22 and are not repeated here.
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adenocarcinomas to squamous cell carcinomas was found to
be higher in women (27 versus 11) than in men (38 versus 39,
2  4.88, P  0.027). There were no significant differences
in degree of differentiation between squamous and adenocar-
cinomas. However, by definition, all BACs were well differ-
entiated and all large cell carcinomas were poorly differen-
tiated.
FDG PET
MaxSUV and PVCmaxSUV differed significantly
across histologic subtypes (KW, P  0.0001 for both com-
parisons; Table 1; Fig. 1). In pairwise comparisons, both
maxSUV and PVCmaxSUV were significantly lower in
BACs compared with adenocarcinomas (P  0.05 and P 
0.01, respectively), in BACs compared with squamous cell
carcinomas (P  0.001 for both comparisons), and in BACs
compared with large cell carcinomas (P  0.001 for both
comparisons). Adenocarcinomas had lower maxSUV and
PVCmaxSUV values compared with squamous cell carcino-
mas (P  0.01 and P  0.05, respectively) and compared
with large cell carcinomas (P  0.01 for both comparisons).
Squamous cell and large cell carcinomas were not found to
have statistically significantly different values for maxSUV
or PVCmaxSUV.
Tumors with better differentiation had lower maxSUV
(KW, P  0.0001; SR,   0.365, P  0.0001; Table 1; Fig.
2), and also had lower PVC maxSUV (KW, P  0.0001; SR,
  0.415, P  0.0001; Table 1; Fig. 2). In pairwise
comparisons, tumors classified as well differentiated had lower
maxSUV and PVCmaxSUV values than those of any other
differentiation (P 0.001 for all comparisons) and tumors in the
moderate differentiation group had significantly lower maxSUV
and PVCmaxSUV than tumors in the poor differentiation group
(P  0.05 and P  0.01, respectively).
FDG maxSUV was found to correlate significantly with
tumor size (SR,   0.592, P  0.0001; Fig. 3). PVCmaxSUV
had a weaker but still statistically significant correlation with
tumor size (SR,   0.245, P  0.001; Fig. 3).
Ki-67 Score
A total of 109 patients had a primary tumor sample
sufficient for Ki-67 scoring. An additional 27 patients who
did not have a primary tumor sample sufficient for Ki-67
scoring had a tumor sample from a resected lymph node
metastasis which was used for Ki-67 scoring. There was no
significant difference in the range of Ki-67 scores obtained
from primary tumors (mean  49.67, SD  25.80) and those
obtained from lymph node metastases (mean  52.04, SD 
27.95). Therefore, Ki-67 scores from all 136 patients were
included in subsequent analyses.
Ki-67 scores differed significantly across histologic
subtypes (KW, P  0.0001; Table 1; Fig. 1). In pairwise
comparisons, the same differences observed in FDG uptake
were observed in Ki-67 scores. BACs were found to have
lower Ki-67 scores than adenocarcinomas, squamous cell
carcinomas, or large cell carcinomas (P  0.05, P  0.001,
and P  0.001, respectively). Adenocarcinomas were found
to have lower Ki-67 scores than either squamous cell or large
cell carcinomas (P  0.05 and P  0.01, respectively).
Squamous cell and large cell carcinomas were not found to
have significantly different Ki-67 scores.
Similar to the results obtained for FDG uptake, tumors
with better differentiation had lower Ki-67 scores (KW, P 
0.0001; SR,   0.459, P  0.0001; Fig. 2). In pairwise
comparisons, tumors classified as well differentiated had
lower Ki-67 scores than those classified as moderate or
FIGURE 1. The maxSUV (A), PVCmaxSUV (B), and Ki-67
scores (C) of all NSCLCs grouped by histologic subtype: bron-
chioalveolar carcinoma (BAC), adenocarcinoma (Adeno.),
squamous cell carcinoma, and large cell carcinoma (L.C.).
Lines represent means and standard deviations. For all 3
comparisons, differences are significant between BAC and
each other histologic type and between adenocarcinoma
and each other histologic type.
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poorly differentiated (P  0.0001 for both comparisons) and
tumors classified as moderate had significantly lower Ki-67
scores than those classified as poor (P  0.05).
Ki-67 scores for all patients had a significant correlation
with maxSUV (SR,   0.354, P  0.0001; Fig. 4) and a
stronger correlation with PVCmaxSUV (SR,   0.452, P 
0.0001; Fig. 4). Ki-67 scores were unrelated to the size of the
primary tumor (SR,   0.0001 P  0.999; Fig. 3) or to the
cancer stage at the time of presentation (KW, P  0.05).
Although used in this comparison, the previously reported dis-
tribution of stages for this patient cohort has not been repeated
here and can be found in our earlier report.22
In a set of parallel analyses using only those Ki-67
scores obtained from primary tumor tissue (n  109), all of
the relationships reported above between different histologic
and differentiation groups remained significant. Using only
the Ki-67 scores from primary tumor tissue, there was
again a correlation with maxSUV (Spearman’s   0.401;
FIGURE 2. The maxSUV (A), PVCmaxSUV (B), and Ki-67
scores of all NSCLCs (C) grouped by degree of cellular differ-
entiation (well differentiated, moderate, and poor). Lines
represent means and standard deviations. For all 3 compari-
sons, all differences are significant.
FIGURE 3. Correlations between average tumor diameter
and maxSUV (A; Spearman’s   0.592; P  0.0001), be-
tween average tumor diameter and PVCmaxSUV (B; Spear-
man’s   0.245; P  0.001), and between average tumor
diameter and Ki-67 scores for all NSCLCs (C; Spearman’s
  0.001; P  0.999).
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P  0.0001) and a stronger correlation with PVCmaxSUV
(Spearman’s   0.512; P  0.0001).
DISCUSSION
In a previous investigation, we evaluated our cohort of
178 NSCLC patients for differences in FDG uptake (maxSUV
and PVCmaxSUV) across stages.22 The current study adds to
these findings by examining these uptake measurements across
histologic categories within the same population and including
Ki-67 proliferation index as a covariate. To our knowledge, this
is the largest prospective study to relate NSCLC FDG uptake to
histology and the only one employing PVC to correct SUVs for
limitations in PET scanner resolution.
The data presented here confirm previous findings from
retrospective studies and smaller prospective studies which
documented lower FDG uptake in better-differentiated lung
carcinomas,17,24 lower uptake in adenocarcinomas than in
squamous cell carcinomas,14,15,17,25 and lower uptake in
BACs than in non-BAC adenocarcinomas.24,26,27
In addition, our relatively large number of large cell
carcinomas allowed us to accurately measure uptake within
this histologic variant, which was greater than the uptake
observed in adenocarcinomas and not significantly different
than the uptake observed in squamous cell carcinomas (Table
1, Fig. 1). Because the same differences in FDG uptake were
observed using both maxSUV and PVCmaxSUV, and be-
cause there were no differences in average tumor size be-
tween histologic or differentiation subgroups, it seems that
intergroup differences in observed FDG uptake were truly
indicative of differences in tumor glucose metabolism across
histologic subtypes.
This study also represents the largest prospective anal-
ysis of the relationship between Ki-67 score and FDG uptake
in NSCLC. In our series, Ki-67 scores were obtained from
primary tumor resection specimens and core biopsy speci-
mens, and represented both primary tumors and lymph node
metastases. Treating all of these Ki-67 values together as a
group irrespective of the site and method of tissue harvesting
is justified based on the following evidence. Viberti et al have
previously shown a strong correlation between Ki-67 scores
derived from transbronchial core biopsies and primary resec-
tion specimens.28 Also, in breast cancer, Koda et al docu-
mented a very strong correlation (  0.707) between Ki-67
scores derived from primary tumors and their metastatic
regional lymph nodes,29 paralleling similar results by Briffod
et al.30 To our knowledge, this question has not been exam-
ined in lung cancer. In our series, there were no significant
differences between the Ki-67 scores derived from the group
of primary tumors and the Ki-67 scores derived from the
group of malignant lymph nodes. In addition, all of the
correlations and between-groups differences found in this
study were found to be significant whether we included all
Ki-67 scores or only those derived from primary tumors.
These findings show that a mixed sample of Ki-67 scores
from primary NSCLCs and lymph node metastases is a
justifiable covariate to compare with other biologic factors in
NSCLC.
We observed a positive correlation between Ki-67 and
FDG uptake (Fig. 4), confirming that to an extent, NSCLC
primary tumors take up FDG in proportion to the fraction of
cells within them which are actively proliferating. (The cor-
relation was not expected to be strong because FDG is not a
specific tracer of cellular proliferation.) Furthermore, differ-
ences in FDG uptake between histologic subtypes and differ-
entiation groups corresponded with similar differences ob-
served in Ki-67 scores between these groups. These findings
are also in keeping with the results published in the literature,
which indicate that Ki-67 scores are higher in squamous cell
carcinomas compared with adenocarcinomas31–33 and higher
in more poorly differentiated carcinomas.32,33 This clear con-
cordance between FDG uptake and Ki-67 proliferation index
suggests the possibility that differences in cellular prolifera-
tion between NSCLC histologic subtypes may give rise to
commensurate differences in cellular glucose metabolism.
Cellular proliferation is an important consideration in
NSCLC because of its significant relationship with patient
prognosis34,35 and because new methods are emerging for
imaging tumor cell proliferation using PET with the radio-
tracer 18F-fluorothymidine.36 Proliferation imaging with
18F-fluorothymidine is being investigated as a means to
assess prognosis, plan therapy, and assess treatment response
in a variety of cancers.37 On the other hand, FDG uptake
FIGURE 4. Correlations between Ki-67 score and maxSUV
(A; Spearman’s   0.354; P  0.0001) and between Ki-67
score and PVCmaxSUV (B; Spearman’s   0.452; P 
0.0001).
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values have previously been reported to correlate weakly with
tumor cell proliferation in several studies,21,38–40 while some
others have not observed this relationship.18,41 The current study
further elucidates this relationship by demonstrating how both
FDG uptake and cellular proliferation vary with the NSCLC
histologic subtype and degree of differentiation. The results may
inform clinicians and researchers regarding the multiple factors
that affect tumor FDG uptake and the similarities and differ-
ences between FDG PET and proliferation indexes.
It should also be noted that while Ki-67 proliferation
index was chosen as a covariate in this study (because of its
prognostic significance in NSCLC and relevance to emerging
PET imaging techniques), it would also be useful to explore
other biologic factors in relation to FDG uptake. For example,
measuring glucose transporters18,40,42–44 or HIF-1 expres-
sion18 across histologic groups could provide additional in-
sights into the mechanisms affecting FDG uptake.
As previously reported, PVC is an algorithm to correct
for the systematic underestimation of maxSUV that occurs
when imaging small tumors.20,21 Unintentional underestima-
tion occurs due to the finite reconstructed resolution of the
PET scanner, which in current PET systems is coarse enough
so that voxel values are influenced by neighboring voxels in
the tumor or in adjacent normal tissues. For the GE Advance
PET scanner in which these patients were studied, we have
determined that PVC is necessary for tumors smaller than
2.8 cm in diameter, given the reconstruction technique and
filter used.20,21
In our study, after PVC was applied, the strong, posi-
tive correlation between primary tumor size and FDG uptake
was reduced substantially. This finding supports our imple-
mentation of PVC. In contrast, after the application of PVC,
the positive correlation between FDG uptake and Ki-67 score
increased. All relative differences in tumor FDG uptake
observed between histologic or differentiation subgroups re-
mained intact after applying PVC.
In conclusion, in a large, prospectively-recruited cohort
of subjects with NSCLC, we have verified previous reports of
lower FDG uptake at PET in BACs compared with non-BAC
adenocarcinomas, lower uptake in non-BAC adenocarcino-
mas compared with squamous cell carcinomas, and lower
uptake associated with better tumor differentiation. In addi-
tion, we have found that large cell undifferentiated carcino-
mas have a similar level of FDG uptake as squamous cell
carcinomas, which is greater than other histologic types, a
finding not previously reported. These findings are true whether
FDG uptake is quantified as the primary tumor maxSUV or the
PVCmaxSUV, and are paralleled by nearly identical relation-
ships for the tumor proliferative index, assessed by Ki-67 scor-
ing. PVC decreases the dependence of maxSUV on tumor size,
increases its correlation with Ki-67 score, and eliminates its
correlation with tumor stage, as previously reported by our
group.22 PVCmaxSUV should be considered the preferable
method for assessing FDG uptake at PET.
These results clarify the relationship between NSCLC
histologic features and FDG uptake, complementing our
previous reports relating NSCLC FDG uptake to tumor
stage22 and prognosis.19
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